重新审视胶质瘤软脑膜转移的预后因素:临床与分子因素及治疗方式的综合分析
该研究纳入226例伴软脑膜转移的成人胶质瘤患者,其中88.5%为IDH野生型,采用时间依赖Cox分析评估总生存预后因素。结果显示化疗和抗血管生成治疗与更长总生存相关,男性性别和初诊时软脑膜转移与更短总生存相关,女性生存优势一致。
要点
- 化疗和抗血管生成治疗与胶质瘤软脑膜转移患者更长总生存相关。
- 初诊软脑膜转移患者中位总生存12.2个月,短于复发软脑膜转移的20.6个月(P<0.001)。
- 男性性别和初诊软脑膜转移是更短总生存的预测因素,女性生存优势一致。
核心结论
- 化疗和抗血管生成治疗在胶质瘤软脑膜转移患者中显示生存获益。
- 女性生存优势一致,且初诊胶质瘤至软脑膜转移诊断间隔更长提示复发软脑膜转移患者总生存更长。
研究设计与样本
- 纳入2001年至2021年间1495例2至4级胶质瘤患者中的226例软脑膜转移患者,88.5%的软脑膜转移患者为IDH野生型。
- 入组患者需具备IDH突变、1p/19q共缺失和MGMT启动子甲基化状态的完整信息。
- 采用时间依赖Cox分析确定全部患者总生存的预测因素,包括临床、分子和治疗数据。
- 对初诊时软脑膜转移和复发时诊断软脑膜转移的患者进行亚组分析,并在IDH野生型胶质母细胞瘤患者中重复相同分析。
主要发现
- 中位总生存为17.0个月(IQR 9.7-67.1),初诊软脑膜转移患者中位总生存12.2个月 vs 复发软脑膜转移患者20.6个月(P<0.001)。
- 全部患者中,化疗和抗血管生成治疗是更长总生存的预测因素,男性性别和初诊软脑膜转移是更短总生存的预测因素。
- 初诊软脑膜转移患者中,较高KPS、化疗和抗血管生成治疗是更长总生存的预测因素,男性性别是更短总生存的预测因素。
- 复发软脑膜转移患者中,化疗和初诊胶质瘤至软脑膜转移诊断间隔更长是更长总生存的预测因素,男性性别是更短总生存的预测因素。
- 在IDH野生型胶质母细胞瘤患者中观察到相似趋势。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To comprehensively investigate prognostic factors, including clinical and molecular factors and treatment modalities, in adult glioma patients with leptomeningeal metastases (LM). METHODS: Total 226 patients with LM (from 2001 to 2021 among 1495 grade 2 to 4 glioma patients, 88.5% of LM patients being IDH-wildtype) with complete information on IDH mutation, 1p/19q codeletion, and MGMT promoter methylation status were enrolled. Predictors of overall survival (OS) of entire patients were determined by time-dependent Cox analysis, including clinical, molecular, and treatment data. Subgroup analyses were performed for patients with LM at initial diagnosis and LM diagnosed at recurrence (herein, initial and recurrent LM). Identical analyses were performed in IDH-wildtype glioblastoma patients. RESULTS: Median OS was 17.0 (IQR 9.7-67.1) months, with shorter median OS in initial LM than recurrent LM patients (12.2 vs 20.6 months, P < 0.001). In entire patients, chemotherapy and antiangiogenic therapy were predictors of longer OS, while male sex and initial LM were predictors of shorter OS. In initial LM, higher KPS, chemotherapy, and antiangiogenic therapy were predictors of longer OS, while male sex was a predictor of shorter OS. In recurrent LM, chemotherapy and longer interval between initial glioma and LM diagnoses were predictors of longer OS, while male sex was a predictor of shorter OS. A similar trend was observed in IDH-wildtype glioblastoma. CONCLUSION: Active chemotherapy and antiangiogenic therapy demonstrated survival benefit in glioma patients with LM. There is consistent female survival advantage, whereas longer interval between initial glioma diagnosis and LM development suggests longer OS in recurrent LM.
引用
- Park YW, Han K, Kim S, et al. Revisiting prognostic factors in glioma with leptomeningeal metastases: a comprehensive analysis of clinical and molecular factors and treatment modalities. J Neurooncol. 2023. PMID: 36841906. doi:10.1007/s11060-022-04233-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。